share_log

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

CytoMed Therapeutics將在基準公司即將舉行的發現一對一投資者會議上發表演講
PR Newswire ·  2023/11/14 20:47

SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced it will be presenting at The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the New York Athletic Club in New York City.

新加坡2023年11月14日 /PRNewswire/ — CytoMed Therapeutics Limited(納斯達克股票代碼:GDTC)(“CytoMed” 或 “公司”),a 新加坡總部位於基準公司的生物製藥公司專注於利用其專有技術開發用於治療各種癌症的新型捐贈者衍生的基於細胞的異基因免疫療法,今天宣佈將在The Benchmark Company的第12屆大會上發表演講第四 年度發現一對一投資者會議即將舉行 12 月 7 日,星期四第四,2023 年在紐約體育俱樂部舉行 紐約市

The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which CytoMed Therapeutics will be participating in one-on-one meetings with investors and analysts throughout the day.

該會議以獨特的一對一形式爲新興成長型和充滿活力的上市公司提供了與機構和個人投資者接觸的機會,在此期間,CytoMed Therapeutics將全天參加與投資者和分析師的一對一會議。

To schedule a one-on-one meeting with the company, you may submit your request online via the link provided upon registration. To register for the conference, please visit

要安排與公司的一對一會議,您可以通過註冊時提供的鏈接在線提交申請。要報名參加會議,請訪問

About The Benchmark Company

關於基準公司

The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm's sales, trading, and equity research capabilities. .

Benchmark Company是一家以機構爲中心、以研究爲導向、銷售交易和投資銀行業務 公司。我們 成立於 1988 年,總部位於紐約 Ci試試。O我們的重點是通過籌集資金、提供戰略諮詢服務、進行有見地的研究以及利用公司的銷售、交易和股票研究能力發展機構贊助來促進企業客戶的長期成功。 。

About CytoMed Therapeutics Limited (CytoMed)

關於 CytoMed Therapeutics 有限公司(CytoMed

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector. It is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating hematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. For more information, please visit and follow us on Twitter @CytomedSG,on LinkedIn, and Facebook

CytoMed 成立於 2018 年,從科學、技術和研究署 (A*STAR) 分拆出來, 新加坡的 公共部門領先的研發機構。它是一家生物製藥公司,專注於利用其許可的專有技術來開發用於治療人類癌症的新型細胞免疫療法。新技術的開發受到現有CAR-T療法在治療血液惡性腫瘤方面的臨床成功以及將CAR-T原理推到實體瘤治療方面當前的臨床侷限性和商業挑戰的啓發。欲了解更多信息,請在 Twitter @CytomedSG、LinkedIn 和 Facebook 上訪問並關注我們

SOURCE CytoMed Therapeutics Limited

來源 CytoMed 治療有限公司

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論